Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cost effectiveness in treating ventilator-associated pneumonia.

M S Niederman1

  • 1Division of Pulmonary and Critical Care Medicine, Winthrop-University Hospital, Mineola, New York, USA. mniederman@winthrop.org

Critical Care (London, England)
|December 12, 2001
PubMed
Summary

Ventilator-associated pneumonia (VAP) is a frequent intensive care unit illness. Accurate diagnosis, therapy, and prevention strategies can significantly lower the economic burden associated with VAP management, especially when resistant organisms are involved.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspiration pneumonia.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2022
Same author

Multi-drug resistant organism infections in a medical ICU: Association to clinical features and impact upon outcome.

Medicina intensiva·2017
Same author

An Economic Model to Compare the Different Empiric and First/Second Line Treatment Regimens for Suspected Methicillin-Resistant Staphylococcus Aureus Nosocomial Pneumonia.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Response to "Treatment guidelines for nosocomial pneumonia: Agreeing to disagree".

The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses·2012
Same author

Initial antimicrobial treatment of hospital acquired pneumonia in adults: A conference report.

The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses·2012
Same author

Fluoroquinolones in the management of community-acquired pneumonia.

International journal of clinical practice·2010

Area of Science:

  • Critical Care Medicine
  • Infectious Diseases
  • Health Economics

Background:

  • Ventilator-associated pneumonia (VAP) is a common nosocomial infection in intensive care units (ICUs).
  • VAP management costs escalate with resistant organisms and prolonged, potentially unnecessary, treatments.
  • The economic impact of VAP necessitates efficient diagnostic and therapeutic approaches.

Purpose of the Study:

  • To highlight the significant cost implications of ventilator-associated pneumonia (VAP).
  • To emphasize the role of accurate diagnosis, targeted therapy, and effective prevention in mitigating VAP costs.
  • To underscore the financial benefits of optimizing VAP management strategies.

Main Methods:

  • Review of existing literature on VAP incidence and management costs.

Related Experiment Videos

  • Analysis of cost drivers including resistant pathogens and treatment duration.
  • Evaluation of strategies for improved diagnosis, therapy, and prevention.

    • Main Results:

    • Infections involving resistant organisms significantly increase VAP management expenses.
    • Prolonged and inappropriate therapies further exacerbate the economic burden of VAP.
    • Effective diagnostic and therapeutic interventions are crucial for cost containment.

    Conclusions:

    • Optimizing the diagnosis, therapy, and prevention of ventilator-associated pneumonia is essential for reducing healthcare costs.
    • Implementing evidence-based strategies can mitigate the financial impact of VAP, particularly in the presence of antimicrobial resistance.
    • Reducing unnecessary and prolonged treatments is key to managing VAP economically.